由于交易,管理收入增长和SaaS采用,NexgenRx在2024年第二季度的收入增长了19.31%,达到408万美元. NexgenRx records a 19.31% Q2 2024 revenue increase to $4.08M, driven by transaction, admin revenue growth, and SaaS adoption.

NexgenRx是加拿大的TPA和技术提供者,收入增长19.31%,2024年的Q2收入增加到4.08M,其驱动因素是交易、行政收入增长和采用SaaS。 NexgenRx, a Canadian TPA & tech provider, records 19.31% Q2 2024 revenue increase to $4.08M, driven by transaction, admin revenue growth, and SaaS adoption. EBITDA正增长17%,达到376.5KK,保持了1.809M的强劲现金状况。 Positive EBITDA rises by 17% to $376.5K, maintaining a strong cash position of $1.809M. NexgenRx注重为客户制定SaaS解决方案,以有效管理福利计划。 NexgenRx focuses on developing SaaS solutions for clients to manage benefit plans effectively.